Lorbrena (lorlatinib) Letter of Medical Necessity
Lorbrena (lorlatinib) is a third-generation ALK inhibitor used first-line and after progression on other ALK inhibitors. Some payers require alectinib or brigatinib first. A Letter of Medical Necessity citing CROWN data, CNS disease, or resistance mutations usually supports approval.
FDA-Approved Indications
- ● ALK-positive metastatic non-small cell lung cancer
Why Lorbrena Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. ALK-positive biomarker report not attached
- 2. Payer requires a different ALK inhibitor first (alectinib or brigatinib)
- 3. Line of therapy and prior ALK inhibitor history not documented
- 4. Baseline lipid panel not documented
- 5. Specialty pharmacy requirement not met
What to Include in a Lorbrena Letter of Medical Necessity
Attach the ALK biomarker report, any resistance-mutation testing on progression, imaging documenting CNS involvement, and prior ALK inhibitor history with response and progression dates. Document baseline lipids and a plan for lipid and CNS adverse-event monitoring, and cite the NCCN category of evidence.
Key clinical evidence to cite:
- ✓ CROWN Phase 3 trial — markedly longer progression-free survival than crizotinib, sustained at 5 years
- ✓ High intracranial response rates, including in patients with baseline brain metastases
- ✓ Activity against resistance mutations (e.g., ALK G1202R) after earlier ALK inhibitors
Relevant guidelines:
- 📖 NCCN Non-Small Cell Lung Cancer Guidelines
- 📖 ASCO/OH Therapy for Stage IV NSCLC with Driver Alterations
- 📖 ESMO Oncogene-Addicted Metastatic NSCLC Guideline
Lorbrena Prior Authorization Criteria
Standard criteria across major US payers for Lorbrena. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Line of therapy and prior ALK inhibitor history not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Lorbrena
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Lorbrena Prior Authorization FAQ
Why was my Lorbrena prior authorization denied?
The most common denial reasons for Lorbrena are: ALK-positive biomarker report not attached; Payer requires a different ALK inhibitor first (alectinib or brigatinib); Line of therapy and prior ALK inhibitor history not documented; Baseline lipid panel not documented; Specialty pharmacy requirement not met.
What should a Lorbrena Letter of Medical Necessity include?
Attach the ALK biomarker report, any resistance-mutation testing on progression, imaging documenting CNS involvement, and prior ALK inhibitor history with response and progression dates. Document baseline lipids and a plan for lipid and CNS adverse-event monitoring, and cite the NCCN category of evidence.
Which payers cover Lorbrena?
Lorbrena is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.